Introduction
============

Bacterial pathogens are masters of survival. They usually distinguish themselves from other strains within their species by a drastic change in lifestyle. Although closely related strains dwell in the soil or aqueous environments, pathogenic strains have evolved to thrive within a host. This brings the advantage of a "niche" existence, but it also comes with many challenges. A pathogen must successfully infiltrate the host's tissues by attaching to cells (sometimes entering them) and subverting the cell's natural functions for its own ends, all while avoiding the host's immune system and other defenses. In the ongoing evolutionary arms race between pathogens and their hosts, pathogens tend to "think big," generally targeting pathways that control important cellular functions like cytoskeletal dynamics ([@bib28]), initiation of cell death ([@bib9]), or autophagy and cellular membrane homeostasis ([@bib88]; [@bib12]; [@bib3]; [@bib30]). It is no wonder that pathogens have evolved a large variety of tools to target one of the most ubiquitous of all eukaryotic signaling mechanisms: phosphorylation by protein kinases.

The human genome encodes ∼500 putative protein kinase genes, which correspond to 2% of all eukaryotic genes. This relatively small percentage of protein kinase--encoding genes is opposed by an enormous number of targets that are regulated by protein kinases. It has been estimated that roughly 30% of all cellular proteins may be modified by protein kinase activity ([@bib48]). Consequently, kinases give rise to a vast network of interwoven signaling pathways, and the sheer complexity of eukaryotic kinase signaling networks still baffles scientists, biochemists, and system biologists alike. The field has made enormous progress toward understanding kinases on a biochemical and structural level by following specific "threads" of kinase regulatory cascades, starting from receptor activation to cellular consequences on the transcriptional level. However, in many cases, the field still lacks a deeper understanding about how seemingly "discrete" signaling pathways are communicating, thereby giving rise to a cellular fate that cannot be predicted based on additive outcomes of individual pathways.

An increasingly popular strategy to attempt to understand complex eukaryotic pathways is to study the mechanisms that pathogens use to subvert them. Invading pathogens specifically target signaling networks at a certain point, irreversibly provoking the downstream event they require to meet their needs. To this end, the study of how bacterial pathogens manipulate complex networks like the MAPK and nuclear factor κB (NF-κB) kinase pathways could illuminate otherwise inscrutable but important mechanisms of regulation and crosstalk in these pathways. Even a "simple" cascade can be regulated by diverse mechanisms, including dephosphorylation, binding to regulators, subcellular localization, and degradation. We will describe examples of all of these regulatory principles, show how pathogens have taken advantage of them to achieve a dominating up- or down-regulation of kinase activity ([Table I](#tbl1){ref-type="table"}), and present insights that we have gained into the pathways themselves.

###### 

Effectors manipulating host kinase signaling

  Pathogen                       Effector        Activity                 Host targets      Pathway                         Phenotype                                                         Reference
  ------------------------------ --------------- ------------------------ ----------------- ------------------------------- ----------------------------------------------------------------- -----------------------------
  *P. gingivalis*                Fimbriae        Binding                  CXCR4/ TLR2       NF-κB inhibition                Decreased ROS production                                          [@bib29]
  *M. tuberculosis*              ?               Binding                  CR-3              p38 MAPK activation             Decreased CD1 expression                                          [@bib21]
  *Shigella* subspecies (ssp).   IpaH9.8         E3 ligase                NEMO/ ABIN-1      NF-κB inhibition                Inhibition of pro-inflammatory responses                          [@bib8]
  *Shigella* ssp.                OspG            Kinase                   UbcH5             NF-κB inhibition                Inhibition of pro-inflammatory responses                          [@bib41]
  *Shigella* ssp.                OspF            Phosphothreonine lyase   ERK1/2            ERK inhibition                  Inhibition of pro-inflammatory responses                          [@bib6]; [@bib43]; [@bib45]
  *Shigella* ssp.                OspE            Binding                  Focal adhesions   ILK activation                  Stabilization of intestinal lining                                [@bib42]
  *A. salmonicida*               AopP            Acetyltransferase        ?                 NF-κB inhibition                Inhibition of pro-inflammatory responses                          [@bib20]
  *V. parahaemolyticus*          VopA/P          Acetyltransferase        MKKs              MAPK inhibition                 Growth arrest                                                     [@bib81]
  EHEC                           EspG            Binding                  ARFs/PAKs         Arf inhibition/PAK activation   Reprogramming of intracellular trafficking                        [@bib78]
  EPEC/EHEC                      NleH            Binding                  RPS3              partial NF-κB inhibition        Increased bacterial colonization, decreased mortality of host     [@bib87]
  EPEC                           NleE            ?                        IKKβ              NF-κB inhibition                Inhibition of pro-inflammatory responses                          [@bib59]; [@bib85]
  EPEC                           NleC/NleD       Proteases                RelA              NF-κB inhibition                Inhibition of IL-8 secretion                                      [@bib10]; [@bib66]
  *L. pneumophila*               LegK1           Kinase                   IκB               NF-κB activation                Induction of pro-inflammatory responses                           [@bib23]
  *Yersinia* ssp.                YopJ            Acetyltransferase        MKKs              MAPK/ NF-κB inhibition          Induction of apoptosis/inhibition of pro-inflammatory responses   [@bib58]
  *Yersinia* ssp.                Invasin/YadA    Binding                  β1-integrins      FAK activation                  Actin rearrangements/bacterial uptake                             [@bib82]
  *Yersinia* ssp.                YopH            Phosphatase              Fyb               Fyn inhibition                  Inhibition of phagocytosis                                        [@bib93]
  *Yersinia* ssp.                YopH            Phosphatase              FAK/p130Cas       FAK inhibition                  Disruption of focal adhesions/inhibition of phagocytosis          [@bib13]
  *B. anthracis*                 Anthrax toxin   Protease                 MKKs              MAPK inhibition                 Induction of apoptosis                                            [@bib2]
  *B. anthracis*                 LF              Protease                 MEK1              MAPK inhibition                 Induction of apoptosis                                            [@bib65]
  *P. aeruginosa*                ExoT            ADP-ribosyltransferase   Crk               Crk inhibition                  Inhibition of invasion                                            [@bib69]

Targeting of the NF-κB and MAPK pathways
========================================

The evolution of eukaryotic immune recognition in the face of ever-changing bacterial phenotypes is a constant battle. The host's innate immune system is poised to be triggered by signs of bacterial challenge, so-called pathogen-associated molecular patterns (PAMPs), which include characteristic molecules associated with infecting pathogens such as peptidoglycan, lipopolysaccharide, lipoteichoic acid, or flagellin ([@bib44]; [@bib51]). These are detected by eukaryotic pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs), and mannose receptors, or the family of cytoplasmic nucleotide-binding oligomerization domain containing protein (NOD)-like receptors (NLRs; [@bib52]; [@bib36]). When bound to their PAMP ligand, PRRs induce signaling cascades, most commonly NF-κB and MAPK pathways, which in turn trigger pro-inflammatory responses such as the up-regulation of cytokines and antimicrobial peptides or activation of the complement cascade ([@bib76]). For a recent review of innate immunity, please see [@bib11]. However, pathogens have developed diverse mechanisms to counter the immune system, including disruption of immune recognition, inhibition of pro-inflammatory responses, or direct induction of immune cells ([Fig. 1](#fig1){ref-type="fig"}).

![**Regulation of MAPK and NF-κB pathways and their manipulation by bacterial effectors.** Bacterial infection triggers PAMP-dependent activation of PRRs at the host cell membrane. Receptor activation triggers MKKK phosphorylation, which in turn activates MAPK pathways and the NF-κB pathway via activation of the IKK complex. IKK phosphorylates IκB, which then becomes polyubiquitinated and removed by proteasomal degradation. Degradation of IκB exposes the NLS on NF-κB, which subsequently undergoes nuclear translocation and binds to κB sites in target promoters to stimulate transcription of genes required for pro-inflammatory responses, such as cytokines and chemokines, and genes involved in cell proliferation. Activation of NF-κB also leads to surface expression of receptors such as CEACAMs, which are hijacked by pathogens to promote their attachment to the host cell surface. Some κB site-containing promoters require RPS3 as a transcriptional co-factor in addition to NF-κB. RPS3 nuclear translocation is dependent on its phosphorylation by IKKβ. Bacterial pathogens manipulate both MAPK and NF-κB pathways either by acting as inhibitors (red boxes) or activators (green box) of individual components.](JCB_201107132_RGB_Fig1){#fig1}

Activation of the NF-κB and MAPK pathways results in a cascade of activated kinases that ultimately leads to a transcriptional response. For the MAPK signaling pathway, three types of kinases, herein referred to as MAP kinase kinase kinase (MKKK), MAP kinase kinase (MKK), and MAPK, are sequentially phosphorylated, ending with the phosphorylation of MAPK. The activated MAPK translocates to the nucleus to activate by phosphorylation proteins required for transcription of genes, including pro-inflammatory signaling molecules ([@bib94]). The NF-κB pathway is also activated by phosphorylation. In this case, it is activated by the IκB kinase kinase (IKK) complex, which in turn phosphorylates the α subunit of inhibitor of NF-κB (IκB), the cytoplasmic binding partner of NF-κB ([Fig. 1](#fig1){ref-type="fig"}). Phosphorylation of IκB leads to its poly-ubiquitination and proteolytic degradation, resulting in exposure of the NLS on the now unbound NF-κB ([@bib4]). This promotes nuclear translocation of NF-κB and transcriptional activation of genes containing a κB site. Some NF-κB--dependent genes require an additional cofactor, the ribosomal protein S3 (RPS3), for their transcription ([@bib86]). RPS3 nuclear translocation is promoted by IKKβ phosphorylation ([@bib87]). The NF-κB pathway also activates genes involved in the pro-inflammatory response, and, possibly more importantly, genes involved in the antiapoptotic response ([@bib7]; [@bib90]). Bacterial pathogens have devised a multitude of strategies to interfere with NF-κB signaling, often on more than one level, highlighting the importance of inhibiting this particular pathway for pathogen survival.

Manipulation of the NF-κB pathway
=================================

YopJ: an equal opportunity acetyltransferase.
---------------------------------------------

*Yersinia* spp. has devised one of the most efficient strategies to date to disrupt the innate immune response and promote apoptosis in infected cells using one molecule, YopJ ([@bib63], [@bib64]). This 32-kD effector is injected from the pathogen directly into the host's cytoplasm through a needle-like complex called type III secretion system (T3SS). YopJ (also termed YopP) blocks all the MAPK pathways and the NF-κB pathway by preventing the activation of all MKKs and IKKβ (but not IKKα; [Fig. 1](#fig1){ref-type="fig"}; [@bib61]). Originally, bioinformatic tools identified YopJ as an effector that contained a catalytic domain similar to a cysteine protease ([@bib62]). However, biochemical analysis of YopJ revealed that the protein requires an intact catalytic triad for its inhibitory acetyltransferase activity; a novel posttranslational modification that directly competes with phosphorylation. This effector inhibits kinase activation by modifying serine and/or threonine residues in the activation loop with an acetyl group from acetyl-CoA, thereby preventing their modification by phosphorylation ([@bib61]; [@bib80]; [@bib53]; [@bib58]; [@bib32]). During an infection with *Yersinia*, host cell signals for both survival and apoptosis are normally induced. However, with *Yersinia* strains containing YopJ, the default path will always be death because YopJ blocks the survival pathway. Using a yeast genetic screen, a conserved site on all MKKs and IKKβ, but not IKKα, was revealed to be the docking site for YopJ ([@bib32]). As many signaling molecules are conserved in yeast, this genetically tractable system has become a very useful tool to characterize the molecular activity of bacterial effectors. The analysis of YopJ revealed Ser/Thr acetylation as a novel posttranslational modification and was one of the first examples to highlight the use of competitive posttranslational modifications for directing signaling ([@bib58]). Additionally, YopJ is an example of a protein that possesses an enzymatic activity different from what was predicted through bioinformatics, thereby demonstrating the limits of using any one tool for studying unknown signaling molecules.

Other homologues of YopJ have been analyzed but their targets are less clear. The *Salmonella* Typhimurium homologue AvrA seems to target different host proteins and play multiple roles that vary during the course of infection ([@bib47]). For example, early on during infection, it inhibits NF-κB signaling ([@bib16]; [@bib38]). During later stages of infection, it acetylates MKKs such as MKK7 to shut off the JNK pathway, which is activated early during *S.* Typhimurium infection ([@bib17]). Another YopJ homologue, the effector AopP from the fish-pathogen *Aeromonas salmonicida*, inhibits NF-κB signaling using the same catalytic mechanism on another phosphorylated target, possibly downstream of IκB phosphorylation ([@bib20]).

Binding NEMO: Ubiquitination by *Shigella flexneri* IpaH9.8 blocks NF-κB.
-------------------------------------------------------------------------

*S. flexneri*, an intracellular Gram-negative gastrointestinal pathogen capable of causing dysentery, blocks the NF-κB pathway on several levels to ensure silencing of immune responses. Upon invasion of epithelial cells, the NF-κB cascade would typically be activated when *S. flexneri* lipopolysaccharide binds to the cytoplasmic NLR NOD1, which causes enhanced oligomerization of NOD1 and recruitment of the serine/threonine kinase receptor-interacting protein 2/RIP-like interacting CLARP kinase (RIP2/RICK), and NF-κB essential modulator (NEMO), a regulatory subunit of the IKK complex ([@bib25]). However, *S. flexneri* possesses the effector IpaH9.8, a protein injected from the pathogen directly into the host's cytoplasm through the T3SS and that possesses E3 ligase activity for NEMO. IpaH9.8 simultaneously binds NEMO and ABIN-1, an ubiquitin-binding adaptor protein, and promotes polyubiquitination of NEMO ([Fig. 1](#fig1){ref-type="fig"}). Polyubiquitinated NEMO undergoes proteolytic degradation, thus inhibiting NEMO-dependent activation of the IKK complex ([@bib60]; [@bib74]; [@bib8]). Interestingly, inhibition by IpaH9.8 is stronger in response to NOD1 than TNF, and further study may give insight to how upstream signals bias these pathways ([@bib8]).

In contrast, the *S. flexneri* T3SS-injected effector, OspG, blocks the cascade further downstream by preventing polyubiquitination and thus degradation of IκB, the inhibitor of NF-κB ([@bib41]). OspG is a protein kinase with an unknown phosphorylation target that binds ubiquitinylated E2 ubiquitin-conjugating enzymes, including the E2 specific for IκB---UbcH5---and prevents the transfer of ubiquitin onto phosphorylated IκBα by an E3 ubiquitin ligase ([Fig. 1](#fig1){ref-type="fig"}). Inappropriate association of protein domains is a subversive mechanism used to redirect signaling systems, and has led to a greater understanding of many signaling pathways. Examples of this are seen with oncogenic viruses (v-abl), lethal somatic chromosomal translocations (Bcr-Abl; [@bib35]), bacterial extracellular molecules (such as fimbriae), and other pathogenic effectors (e.g., EspG).

Modulation of host defenses by extracellular scaffolding.
---------------------------------------------------------

*Porphyromonas gingivalis*, a periopathogen, uses proteinaceous extracellular structures---fimbriae ([@bib70])---to scaffold both the chemokine receptor 4 (CXCR 4) and the Toll-like receptor TLR2 on human monocytes together in lipid rafts. The crosstalk between CXCR4 and TLR2 results in elevated levels of cAMP, which acts to stimulate the immunomodulatory cAMP-dependent protein kinase A (PKA) and induce a negative feedback loop to suppress CXCR4 function. The authors hypothesize that PKA acts downstream of CXCR4 to inhibit TLR2-dependent, NF-κB--induced TNF activation (inflammatory cytokine), and trigger increased expression of the immunosuppressive cytokine IL-10. The ultimate outcome of this subtle but efficient manipulation of NF-κB signaling is diminished production of nitric oxide (NO), which is usually generated by macrophages as an inflammatory response and secreted as free radicals to fight off pathogens. Suppression of the inflammatory response and NO secretion results in prolonged survival of *P. gingivalis* ([@bib29]). Thus, the pathogen uses an extracellular scaffolding protein to redirect signaling pathways.

Inhibition of the NF-κB pathway by EPEC/EHEC Nle proteins.
----------------------------------------------------------

The binding affinity of the NF-κB p50/p65 heterodimer to DNA is greatly increased by the NF-κB binding partner RPS3 ([@bib86]). This regulator of NF-κB allows specificity in expression of target genes, such as those involved in cytokine production and host defense against enterohemorrhagic *Escherichia coli* (EHEC). NleH1 and NleH2 are a pair of highly conserved T3SS effectors from both enteropathogenic *E. coli* (EPEC) and EHEC. These effectors contain a conserved Ser/Thr kinase domain and a PDZ-binding motif, and are implicated in blocking apoptosis during infection ([Fig. 1](#fig1){ref-type="fig"}; [@bib34]; [@bib50]). Both NleH1 and NleH2 are also capable of binding RPS3 independent of their kinase activity ([@bib22]). Binding of EHEC NleH1 to RPS3 inhibits RPS3 phosphorylation by IKKβ, which sequesters RPS3 in the cytoplasm and prevents its nuclear translocation, thereby disrupting transcriptional up-regulation of RPS3-dependent genes ([@bib22]). The presence of NleH1 leads to increased bacterial colonization and diarrhea but, interestingly, decreases mortality in a piglet infection model, a paradoxical effect that perhaps promotes the spread of the bacteria to other hosts ([@bib87]). Studies of NleH1 have highlighted the essentiality of RPS3 phosphorylation by IKKβ and have shown how altering only the specificity of NF-kB through RPS3 inhibition compromises defenses and affects cytokine expression ([@bib87])

Another EPEC effector, NleE, blocks NF-κB activation by inhibition of IKKβ phosphorylation. The activity of NleE is enhanced by a second effector, NleB ([@bib59]; [@bib85]). Recently, NleC and NleD, members of a family of Zn-dependent metalloproteases, were identified in EPEC. These proteases specifically cleave and inactivate RelA (p65), a subunit of NF-κB, and JNK, respectively, thus blocking NF-κB and activator protein 1 (AP-1) activation. The net result of the inhibition of NF-κB by these bacterial effectors is strong inhibition of the pro-inflammatory cytokine IL-8 ([@bib10]; [@bib66]; [@bib92]).

Activation of the NF-kB pathway by pathogenic effectors.
--------------------------------------------------------

*Listeria monocytogenes* has been reported to cause local inflammation at the primary site of infection to attract monocytes, which they invade and use as a vehicle to spread throughout the host and cause systemic infection ([@bib26]). Other pathogens induce NF-κB activation to trigger enhanced surface expression of pathogen receptors on host cells. Examples of this include *Chlamydophila pneumoniae*, which causes an NF-κB--dependent increase in monocyte chemotactic protein 1 (MCP-1) by endothelial cells ([@bib56]) or *Neisseria gonorrhoeae*, which uses the NF-κB pathway to up-regulate carcinoembryonic antigen-related cellular adhesion molecules (CEACAMs; [@bib57]). Further reasons for NF-κB activation include permeabilization of the vasculature and superficial cell layers to enable pathogens to invade deeper tissue layers or the circulatory system, or, as in the case of *S.* Typhimurium, to trigger the reactive oxygen species (ROS)-promoted formation of a new respiratory chain, which provides the pathogen with a growth advantage over the commensal microbiota ([@bib89]).

Some pathogens secrete effector proteins into the host specifically to evoke NF-κB activation. An example is the *Legionella pneumophila* type IV secreted effector LegK1, which is a Ser/Thr kinase that specifically phosphorylates IκB to induce its ubiquitination and degradation, allowing NF-κB to activate downstream pro-inflammatory responses ([Fig. 1](#fig1){ref-type="fig"}; [@bib23]). Interestingly, LegK1 also appears to have an antiapoptotic effect. It can be speculated that a wide range of pathogens cause a well-timed burst of pro-inflammatory responses upon initial infection to exploit the benefits described earlier, only to switch it off at a later stage of infection using specific effector proteins that inhibit the NF-κB pathway. LegK1 is an IKK mimic that does not require phosphorylation of its activation loop and thereby is regulated independently of the host signaling machinery ([@bib23]).

Manipulation of the MAPK pathway
================================

Inhibition of antigen presentation by MAPK activation.
------------------------------------------------------

Interference by mycobacteria of MAPK signaling pathways by usurping p38 to interfere with CD1 surface expression plays a pivotal role in many aspects of immune modulation ([@bib21]). CD1 belongs to a family of surface glycoproteins, which are expressed on antigen-presenting cells (APCs) and are responsible for presenting lipid antigens such as mycobacterial cell wall components to specific T cells. Mycobacteria such as *Mycobacterium tuberculosis* and *Mycobacterium bovis* interact with complement receptor 3 (CR-3) on the surface of APCs, leading to CR-3--mediated phagocytosis ([@bib77]). CR-3 binding results in phosphorylation of the MAPK p38, which, in turn, leads to phosphorylation of the downstream effector activating transcription factor (ATF-2). Activated ATF-2 is able to bind to the CD1A promoter region and decrease CD1 transcription. As a result, CD1 expression and surface presentation is reduced. Thus, the phagocytosed pathogen's induction of p38 prevents surface display of mycobacterial antigens on APCs by inhibition of CD1 expression, which might allow mycobacteria to evade T cell surveillance during infection in vivo ([@bib21]). The manipulation of these signaling pathways also results in arrest of phagosome maturation in macrophages ([@bib37]) and inhibition of class II MHC expression by macrophages ([@bib67]). These studies highlight a mechanism that uses MAPK signaling to reduce T cell recognition ([@bib21]).

Targeting of MKKs by anthrax toxin.
-----------------------------------

Anthrax toxin, secreted by *Bacillus anthracis*, is another virulence factor that can inhibit MAPK signaling. It is a protease that reaches the host's cytoplasm through lipid raft-mediated uptake and hydrolyses MKKs ([@bib49]; [@bib2]). *B. anthracis* also encodes a toxin called lethal factor (LF) that is a metalloproteinase. LF specifically cleaves the N-terminal extension of MKKs, resulting in a kinase that can no longer interact with its substrate ([@bib18]; [@bib84]; [@bib65]). Importantly, this type of deregulation provided insight into the importance of scaffolding a kinase with a substrate in the MAPK signaling cascade and a potential target for a small molecule LF inhibitor ([@bib39]; [@bib46]).

VopA/P: YopJ's more specific sibling.
-------------------------------------

VopA/P, a *Vibrio parahaemolyticus* effector, is different from its close homologue YopJ in that it can inhibit MAPK signaling pathways but not the NF-κB pathway ([Fig. 1](#fig1){ref-type="fig"}). Despite only inhibiting MAPK, it has a dual function in which it acetylates not only the activation loop of MKKs, thereby inhibiting activation, but also acetylates a conserved lysine in the catalytic loop of MKKs that is required for coordination of the γ-phosphate of ATP. This modification by VopA/P inhibits the binding of ATP ([@bib80]; [@bib81]). By analyzing homologues of different effectors, subtle mechanistic differences are observed that reveal dramatic differences in host cell responses. By inhibiting both NF-κB and MAPK pathways, *Yersinia* YopJ will promote apoptosis. In contrast to YopJ, by inhibiting only MAPK pathways, *V. parahaemolyticus* VopA/P permits survival by allowing activation of the NF-κB pathway.

Crosstalk between p38 and JNK revealed by OspF.
-----------------------------------------------

The phosphothreonine lyase OspF, a *S. flexneri* protein effector, is translocated into the host cell and localizes to the nucleus, where it eliminates a phosphate group from a phosphothreonine residue in the activation loop of the MAPKs ERK1/2 and p38 ([Fig. 1](#fig1){ref-type="fig"}; [@bib45]). This modification is irreversible and the kinase can no longer be activated by phosphorylation. OspF-catalyzed eliminylation inhibits extracellular signal--regulated kinase (ERK)-mediated activation of the mitogen- and stress-activated kinase 1 (MSK1) and MSK2, and thus prevents phosphorylation of histone H3, which is a prerequisite for chromatin reorganization and presentation of κB binding sites at NF-κB--regulated promoters ([@bib15]). The phosphothreonine lyase activity may be preferable to phosphatase activity because of the irreversible nature of the modification. As a consequence, transcriptional up-regulation of genes usually activated by NF-κB is blocked ([@bib79]; [@bib6]; [@bib43]). An unexpected side effect of irreversible p38 dephosphorylation is that JNK and NF-κB activity are actually increased, which suggests that inactivation of p38 may reduce negative feedback by the upstream activator Tak1, highlighting a layer of crosstalk between the pathways ([@bib73]). Interestingly, at least some of the potential downstream effects of JNK and NF-κB activation by OspF are silenced, as OspF has the concomitant effect of reducing transcription of the JNK substrate c-jun, resulting in less phosphorylated c-jun and secreted IL-8 ([@bib73]). It also reduces the accessibility of chromatin to transcription factors, perhaps silencing NF-κB activation. Silencing these potential drawbacks by irreversible deactivation of p38 by inhibiting transcription of downstream substrates shows an interesting mechanism that prevents a "backfire" result by targeting a central signaling pathway like MAPK.

Manipulation of host cytoskeleton and membranes by PI3K/Akt, p21-activated kinase (PAK), and other kinases
==========================================================================================================

The phosphatidylinositol 3-kinase (PI3K)/Akt kinase signaling axis plays an important role in a variety of cellular processes, including cytoskeletal dynamics and migration as well as survival and proliferation ([@bib31]; [@bib68]; [@bib19]). For this reason, the pathway is targeted by many pathogens to reinforce or destroy focal adhesions, which play an integral role in phagocytosis. The PI3K pathway can be triggered by activation of receptor tyrosine kinases or ligand binding to integrins, both leading to phosphorylation of downstream kinase targets ([Fig. 2](#fig2){ref-type="fig"}). Receptor activation leads to recruitment and activation of focal adhesion kinase (FAK) or integrin-linked kinase (ILK). These, in turn, recruit cytoplasmic components of the receptor-linked signaling complex, including the tyrosine kinase Src, the adapter protein Crk, and p130Cas (Crk-associated substrate). Crk phosphorylation leads to strong activation of the small GTPase Rac, which is required for cell motility. Src phosphorylation triggers the association of PI3K with the signaling complex. PI3K phosphorylates phosphoinositols at the D3 position and, depending on the substrate, generates either PI(3)P, PI(3,4)P~2~, or PI(3,4,5)P~3~. Generation of PI(3,4)P~2~ or PI(3,4,5)P~3~ recruits the Ser/Thr kinase Akt (also known as protein kinase B or PKB) to the membrane via its pleckstrin homology (PH) domain, which binds to these phosphoinositols with high affinity ([@bib33]). Akt regulates many cellular processes, including cell migration, proliferation, survival, and metabolism. Activation of PI3K can also activate small GTPases, such as Ras and Rac, which are linked to proliferation and cytoskeletal dynamics, respectively ([@bib72]; [@bib71]).

![**Host signaling pathways exploited for bacterial invasion and colonization.** Ligand-activated transmembrane receptors (integrins or receptor tyrosine kinases) recruit the cytoplasmic signaling proteins FAK or ILK. This in turn leads to binding of p130Cas and Crk, as well as Src and PI3K. PI3K converts PIP2 to PIP3, which binds the pleckstrin homology (PH) domain of Akt. Akt mediates host survival and proliferation signaling. PIP3 also recruits Rho GTPases to the membrane, where they activate actin rearrangements that lead to cellular motility or bacterial uptake through formation of membrane protrusions. Rho GTPases are also activated by Crk. *P. aeruginosa* activates PI3K signaling by integrin or RTK binding to promote cellular uptake. The *S. flexneri* T3SS-injected effector OspE activates PI3K signaling by recruiting ILK. *Yersinia* spp. and *P. aeruginosa* inject T3SS effectors YopH and ExoT to inhibit GTPase activation and phagocytosis (*Yersinia* spp.) or stop invasion at a later stage of infection (*P. aeruginosa*). Direct manipulation of small GTPases is a major target for a variety of bacterial effectors ([@bib1]; [@bib5]).](JCB_201107132_RGB_Fig2){#fig2}

YopH: Terminator of focal adhesion complexes.
---------------------------------------------

Upon binding to macrophages, *Yersinia* spp. disables the phagocytosis machinery by introducing YopH, a tyrosine phosphatase injected through the T3SS ([@bib75]; [@bib27]; [@bib14]). Using a catalytically inactive mutant form as a substrate trap, YopH was shown to bind p130Cas and FAK, which are both members of the focal adhesion complex ([@bib13]). YopH activity thereby disrupts focal adhesion complexes and inhibits phagocytosis, thus limiting the number of internalized bacteria ([@bib55]). YopH also dephosphorylates Fyb (Fyn-binding protein), an immune cell--specific adaptor protein. This disrupts signaling via Fyn and PI3K to small GTPases to induce cytoskeletal rearrangements, which are required to initiate the phagocytic process ([@bib91]; [@bib93]). Deletion of YopH severely decreases virulence of the mutant strains ([@bib14]). Thus, YopH targets and destroys focal adhesions by dephosphorylating key signaling molecules, and highlights the importance of focal adhesions in cell movement and phagocytosis.

Stabilization of the intestinal lining by *S. flexneri*.
--------------------------------------------------------

Enteropathogenic *S. flexneri* bind to the intestinal mucosal layer and invade epithelial cells, where they spread from cell to cell to avoid any extracellular steps. This mode of infection provokes extensive tissue damage and would normally lead to shedding of epithelial cells. However, *S. flexneri* actively stabilizes the epithelial lining by promoting cell adherence. The T3SS effector OspE localizes to focal adhesion sites, where it recruits ILK to promote cell adhesion by inhibiting focal adhesion disassembly. Although ILK appears to act as a scaffold for OspE localization, mutation of its putative kinase residues leads to a reduction in focal adhesion formation. Despite the controversies on whether ILK is actually a kinase, OspE "activation" of ILK leads to an increase in the relative number of focal adhesions, thereby preventing exfoliation of infected mucosal epithelium ([@bib54]; [@bib42]). Several other enteropathogens, such as *E. coli* or *S.* Typhimurium, have been found to possess OspE homologues, and it is hypothesized that they use a similar mechanism for enhanced ILK recruitment to stabilize the intestinal lining during infection to promote bacterial dissemination ([@bib83]).

EspG, a catalytic ... scaffold?
-------------------------------

The EHEC T3SS effector EspG is another example of how bacteria can manipulate the host by "catalytic scaffolding." Both ADP-ribosylation factor (ARF) GTPases and PAKs are substrates of EspG. Arf GTPases are mediators of intracellular membrane trafficking and organelle remodeling, whereas PAKs are Ser/Thr kinases that are activated by Cdc42 and Rac GTPases, thereby regulating actin remodeling and cellular polarity. EspG inhibits Arf GTPase activity by blocking GTPase-activating protein (GAP) binding and thus GTP hydrolysis, while at the same time acting as an allosteric activator of PAK. Both Arf and PAK interact with EspG simultaneously by binding to different surfaces of the effector protein. By recruiting and inactivating Arf, EspG localizes PAK activity to specific membrane compartments, thereby reprogramming processes such as cellular polarity, receptor trafficking, and protein secretion to the pathogen's advantage ([@bib24]; [@bib78]). The study of this pathogenic effector has provided insight into host mechanisms involved in intracellular trafficking.

The complex nature of *Pseudomonas aeruginosa* internalization.
---------------------------------------------------------------

*P. aeruginosa* is another example of a pathogen taking advantage of the interplay between kinase and GTPase signaling pathways to manipulate the cytoskeletal machinery and promote its own internalization. Recent studies with *P. aeruginosa* have revealed the potential interplay of several cytoskeleton-associated GTPases and kinases. [@bib69] used an RNAi screen of *Drosophila* S2 cells to identify host factors required for *P. aeruginosa* invasion. The screen identified Abl tyrosine kinase, the adaptor protein Crk, the GTPases Rac1 and Cdc42, as well as PAK as components of a host signaling pathway leading to internalization of *P. aeruginosa*, and the pathways were subsequently validated by different complementary approaches. Interestingly, the *P. aeruginosa* T3SS effector ExoT takes control of the pathway after pathogen internalization by inhibiting pathogen-induced Abl-dependent Crk phosphorylation, presumably to block further invasion ([@bib69]). Internalization studies with *P. aeruginosa* demonstrated that the phagocytic nature of S2 cells make them ideal for use in identification of host molecules important for bacterial internalization using RNAi-mediated gene inactivation ([@bib69]). Their studies uncovered the diversity of host molecules required for successful invasion by intracellular bacteria.

*P. aeruginosa* also provides an interesting example of how the PI3K pathway can be exploited to promote bacterial tissue invasion. *P. aeruginosa* preferably attaches to and invades epithelial cell layers from the basolateral side. To gain entry from the exposed apical surface, it subverts the PI3K pathway by binding to an unknown receptor present in tight junctions, which recruits and activates PI3K. This triggers the generation of PIP3 at the apical membrane and recruitment of Akt, which in turn redirects trafficking of basolateral membrane components to the apical side by transcytosis. Consequently, PIP3-rich membrane protrusions form on the apical side and facilitate *P. aeruginosa* attachment and entry into the epithelial cell layer ([@bib40]). Studies on this pathogen have thus revealed several points of crosstalk between kinase pathways and signaling cascades mediating either cytoskeletal dynamics or membrane trafficking, all exploited to achieve entry of *P. aeruginosa* into host cells. These studies also highlight the importance of cell polarity in dictating invasion, as it creates a suitable PIP3-rich microenvironment at the apical surface to allow bacterial entry into the host cell ([@bib40]).

Conclusion
==========

Studying the mechanisms of virulence that pathogens use to propagate in a host not only provides potential targets for treatment, but also often provides insight into the host molecules affected. Although some of the future benefits of knowledge gained about eukaryotic signaling may be elusive at this point, the potential for discovery is obvious. The complex and central kinase pathways outlined in this review highlight the importance of using novel angles of investigation. Seeing signaling pathways through the lens of a pathogen reveals unknown intricacies of kinase-mediated signaling pathways.
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